Gerd Zettlmeissl
"Dr. Gerd Zettlmeissl is the former Chief Executive Officer of the Austria-based biotechnology company Intercell AG and is an accomplished vaccine expert and biopharmaceutical business executive. Gerd Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. While at Intercell AG from 2001 to 2011, he built the company from a private start up company to a publicly listed international organization with more than 400 employees. As CEO, he secured regulatory approval and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Gerd Zettlmeissl held senior management roles at Chiron Corp. and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress.
He currently serves on various Supervisory Boards. Inter alia he is Chairman of the Supervisory Board of GlycoVaxyn, a vaccine biotech company in Switzerland, and a member of the Board of Aeras, a non-profit organization developing tuberculosis vaccines." [1]
- Chair, Hilleman Laboratories
- Advisory board, TuBerculosis Vaccine Initiative [2]
Resources and articles
Related Sourcewatch
References
- ↑ Board, Hilleman Laboratories, accessed April 23, 2020.
- ↑ Advisory Committee, TuBerculosis Vaccine Initiative, accessed April 23, 2020.
